COVID-19 pandemic has had tremendous impact on countries across the world and Niger Republic is not left out of the ravaging impact of the virus. The rapid dissemination of the virus across the globe has led to the development of safe and efficacious vaccines at an unprecedented level. While Niger Republic has prioritized COVID-19 vaccination in line with the global plan to attain herd immunity by vaccinating 70% of world's population, the country has continued to struggle to expand coverage of its population. Niger Republic is faced with challenges such as conflict, COVID-19 vaccine hesitancy, poor COVID-19 vaccine demand and inefficient information system, consequently leading to low COVID-19 vaccine demand and uptake. These challenges coupled with the different wave of the pandemic, the latest largely driven by the Omicron variant has slowed down progress towards achieving herd immunity in Niger Republic. There is need for the Nigerien government to scale up vaccination drive as well as implement refined approaches towards achieving the country's herd immunity target. This paper aimed to discuss the current state of COVID-19 vaccination including efforts and challenges towards achieving herd immunity in Niger Republic, thus informing strategies to ramp up COVID-19 vaccination in the country.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.